New heart drug under the microscope: how does acoramidis perform in real life?
NCT ID NCT07235462
First seen Nov 19, 2025 · Last updated May 09, 2026 · Updated 19 times
Summary
This study is observing up to 2,000 adults across Europe who are starting a new medication called acoramidis for a serious heart condition (ATTR-CM). The goal is to see how the drug works in everyday medical practice, not in a strict trial setting. Researchers will track patient characteristics, treatment patterns, heart function, and safety over time to better understand real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitaetsklinik Heidelberg
RECRUITINGHeidelberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.